EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Lacosamide and pregnancy: Data from spontaneous and solicited reports

Piero Perucca iD, Dimitrios Bourikas, P Emanuela Voinescu iD, Lata Vadlamudi iD, Daya Chellun, Thomas Kumke, Konrad J Werhahn, Bettina Schmitz

Epilepsia · 2024

DOI: 10.1111/epi.17924 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, 2024. Verfasst von Piero Perucca und 7 weiteren Autor:innen. Beteiligte Einrichtung: Epilepsy Research Centre, Department of Medicine (Austin Health), University of Melbourne, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Lacosamide, Anticonvulsants, Pregnancy Complications, Pregnancy Outcome. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UCB Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

In pregnancy, it is important to balance the risks of uncontrolled epileptic seizures to the mother and fetus against the potential teratogenic effects of antiseizure medications. Data are limited on pregnancy outcomes among patients taking lacosamide (LCM), particularly when taken as monotherapy. The objective of this analysis was to evaluate the pregnancy outcomes of LCM‐exposed pregnancies.

Methods

This analysis included all reports in the UCB Pharma pharmacovigilance database of exposure to LCM during pregnancy from spontaneous sources (routine clinical settings) or solicited reports from interventional clinical studies and noninterventional postmarketing studies. Prospective and retrospective reports were analyzed separately.

Results

At the data cutoff (August 31, 2021), there were 202 prospective pregnancy cases with maternal exposure to LCM and known outcomes. Among these cases, 44 (21.8%) patients received LCM monotherapy and 158 (78.2%) received LCM polytherapy. Most patients received LCM during the first trimester (LCM monotherapy: 39 [88.6%]; LCM polytherapy: 143 [90.5%]). From the prospective pregnancy cases with maternal LCM exposure, there were 204 reported outcomes (two twin pregnancies occurred in the polytherapy group). The proportion of live births was 84.1% (37/44) in patients who received LCM as monotherapy, and 76.3% (122/160) for LCM polytherapy. The overall proportion of abortions (for any reason) was 15.9% (7/44) with LCM monotherapy, and 22.5% (36/160) with LCM polytherapy. Congenital malformations were reported in 2.3% (1/44) of known pregnancy outcomes with maternal exposure to LCM monotherapy, and 6.9% (11/160) with polytherapy. Significance Our preliminary data do not raise major concerns on the use of LCM during pregnancy. Most pregnancies with LCM exposure resulted in healthy live births, and no new safety issues were identified. These findings should be interpreted with caution, as additional data are needed to fully evaluate the safety profile of LCM in pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LacosamideAnticonvulsantsPregnancy ComplicationsPregnancy OutcomeEpilepsyHumansPregnancyFemaleAdultProspective StudiesRetrospective StudiesPharmacovigilanceAbnormalities, Drug-InducedYoung AdultInfant, Newborn

Stichwörter der Autor:innen

antiseizure medicationscongenital malformationsepilepsypregnancy outcomessafety

Substanzen

LacosamideAnticonvulsants

Autor:innen und Institutionen

  • Epilepsy Research Centre, Department of Medicine (Austin Health), University of Melbourne, Melbourne, Victoria, Australia.
  • Bladin-Berkovic Comprehensive Epilepsy Program, Austin Health, Melbourne, Victoria, Australia.
  • UCB Pharma, Alimos, Greece.
  • Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • University of Queensland Centre for Clinical Research, University of Queensland, Herston, Queensland, Australia.
  • Department of Neurology, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.

ORCID-Profile: Piero Perucca, P Emanuela Voinescu, Lata Vadlamudi

Förderung

  • UCB Pharma

Zitieren

APA

Perucca, P., Bourikas, D., Voinescu, P. E., Vadlamudi, L., Chellun, D., Kumke, T., Werhahn, K. J., & Schmitz, B. (2024). Lacosamide and pregnancy: Data from spontaneous and solicited reports. Epilepsia. https://doi.org/10.1111/epi.17924

Vancouver

Perucca P, Bourikas D, Voinescu PE, Vadlamudi L, Chellun D, Kumke T, et al. Lacosamide and pregnancy: Data from spontaneous and solicited reports. Epilepsia. 2024. doi:10.1111/epi.17924

BibTeX
@article{Perucca2024,
  author = {Perucca, Piero and Bourikas, Dimitrios and Voinescu, P Emanuela and Vadlamudi, Lata and Chellun, Daya and Kumke, Thomas and Werhahn, Konrad J and Schmitz, Bettina},
  title = {Lacosamide and pregnancy: Data from spontaneous and solicited reports},
  journal = {Epilepsia},
  year = {2024},
  doi = {10.1111/epi.17924}
}
Kostenlos starten →